Market Cap
CA$6.6b
Last Updated
2021/04/10 23:18 UTC
Data Sources
Company Financials +
Executive Summary
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Aphria's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: APHA is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 21% a week.
Volatility Over Time: APHA's weekly volatility has increased from 13% to 21% over the past year.
Market Performance
7 Day Return
-10.5%
APHA
-4.8%
CA Pharmaceuticals
1.0%
CA Market
1 Year Return
360.6%
APHA
132.2%
CA Pharmaceuticals
39.2%
CA Market
Return vs Industry: APHA exceeded the Canadian Pharmaceuticals industry which returned 132.2% over the past year.
Return vs Market: APHA exceeded the Canadian Market which returned 39.2% over the past year.
Shareholder returns
| APHA | Industry | Market | |
|---|---|---|---|
| 7 Day | -10.5% | -4.8% | 1.0% |
| 30 Day | -17.9% | -11.6% | 1.4% |
| 90 Day | 87.5% | 8.1% | 7.5% |
| 1 Year | 360.6%360.6% | 132.2%132.2% | 44.0%39.2% |
| 3 Year | 78.6%78.6% | -42.0%-42.8% | 32.2%19.6% |
| 5 Year | 1,239.5%1,239.5% | 350.6%347.4% | 59.4%35.3% |
Long-Term Price Volatility Vs. Market
How volatile is Aphria's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Is Aphria Inc. (TSE:APHA) Expensive For A Reason? A Look At Its Intrinsic Value3 months ago | Simply Wall St
Aphria's (TSE:APHA) Wonderful 798% Share Price Increase Shows How Capitalism Can Build Wealth2 years ago | Simply Wall St
Have Insiders Been Selling Aphria Inc (TSE:APHA) Shares?Valuation
Is Aphria undervalued compared to its fair value and its price relative to the market?
3.41x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: APHA (CA$20.36) is trading above our estimate of fair value (CA$17.76)
Significantly Below Fair Value: APHA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: APHA is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: APHA is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APHA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APHA is overvalued based on its PB Ratio (3.4x) compared to the CA Pharmaceuticals industry average (3.1x).
Future Growth
How is Aphria forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
66.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APHA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: APHA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: APHA's is expected to become profitable in the next 3 years.
Revenue vs Market: APHA's revenue (23.7% per year) is forecast to grow faster than the Canadian market (7.2% per year).
High Growth Revenue: APHA's revenue (23.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: APHA's Return on Equity is forecast to be low in 3 years time (9.5%).
Past Performance
How has Aphria performed over the past 5 years?
-56.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APHA is currently unprofitable.
Growing Profit Margin: APHA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APHA is unprofitable, and losses have increased over the past 5 years at a rate of 56.4% per year.
Accelerating Growth: Unable to compare APHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APHA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: APHA has a negative Return on Equity (-11.24%), as it is currently unprofitable.
Financial Health
How is Aphria's financial position?
Financial Position Analysis
Short Term Liabilities: APHA's short term assets (CA$692.1M) exceed its short term liabilities (CA$293.0M).
Long Term Liabilities: APHA's short term assets (CA$692.1M) exceed its long term liabilities (CA$570.8M).
Debt to Equity History and Analysis
Debt Level: APHA's debt to equity ratio (25.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if APHA's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APHA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if APHA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Dividend
What is Aphria current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APHA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APHA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APHA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of APHA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.1yrs
Average management tenure
CEO
Irwin Simon (61 yo)
2.08yrs
Tenure
CA$18,623,184
Compensation
Mr. Irwin D. Simon has been Chairman of Aphria Inc. since December 27, 2018, serves as its Chief Executive Officer since February 2020 and served as its Interim Chief Executive Officer from March 01, 2019 ...
CEO Compensation Analysis
Compensation vs Market: Irwin's total compensation ($USD14.83M) is above average for companies of similar size in the Canadian market ($USD3.80M).
Compensation vs Earnings: Irwin's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: APHA's management team is considered experienced (2.1 years average tenure).
Board Members
Experienced Board: APHA's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.5%.
Top Shareholders
Company Information
Aphria Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Aphria Inc.
- Ticker: APHA
- Exchange: TSX
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$6.555b
- Shares outstanding: 321.95m
- Website: https://aphriainc.com
Number of Employees
Location
- Aphria Inc.
- 98 Talbot Street West
- Leamington
- Ontario
- N8H 1M8
- Canada
Listings
Biography
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, an...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/10 23:18 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/11/30 |
| Annual Earnings | 2020/05/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.